TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05037760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KER-050 monotherapy
Description: KER-050 administered (SC) for up to 13 cycles. Participants who may have potential benefit from continued treatment, in the opinion of their investigator, may continue in the Long Term Extension after completing 13 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KER-050 monotherapy
Description: KER-050 administered (SC) for up to 13 cycles. Participants who may have potential benefit from continued treatment, in the opinion of their investigator, may continue in the Long Term Extension after completing 13 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KER-050 monotherapy
Description: KER-050 administered (SC) for up to 13 cycles. Participants who may have potential benefit from continued treatment, in the opinion of their investigator, may continue in the Long Term Extension after completing 13 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KER-050 in combination with ruxolitinib
Description: KER-050 administered (SC) for up to 13 cycles in combination with standard of care ruxolitinib. Participants who may have potential benefit from continued treatment, in the opinion of their investigator, may continue in the Long Term Extension after completing 13 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KER-050 in combination with ruxolitinib
Description: KER-050 administered (SC) for up to 13 cycles in combination with standard of care ruxolitinib. Participants who may have potential benefit from continued treatment, in the opinion of their investigator, may continue in the Long Term Extension after completing 13 cycles.
Study: NCT06543849

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Target Temperature Management Treatment
Description: Target Temperature Management Treatment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Target Temperature Management Treatment
Description: Target Temperature Management Treatment
Study: NCT06267937

Intervention type: PROCEDURE
Intervention: Access to surgery
Description: access to surgery after hip fracture

Intervention type: OTHER
Intervention: type of intitution
Description: public or private health care facility
Study: NCT04605497

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM)
Description: Continual use of CGM to monitor blood glucose levels from enrollment through delivery admission \& discharge + additional 10 days during postpartum period

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Self-Capillary Blood Glucose Monitoring (SCBG)
Description: Conventional SCBG 4x/day testing (standard care in Oregon; fasting and 1-hour postprandial) with blinded CGM every 2 weeks SCBG 4 times/day until delivery admission 10 days duration with each blinded CGM wear
Study: NCT05525091

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Feeding Evaluation
Description: Feeding Evaluation with Device
Study: NCT06232850

Intervention type: OTHER
Intervention: Position sense and manual dexterity evaluate
Description: Position sense and manual dexterity evaluate

Intervention type: OTHER
Intervention: Position sense and manual dexterity evaluate
Description: Position sense and manual dexterity evaluate
Study: NCT04969601

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vaccine COMIRNATY® (BNT162b2)
Description: two injections of COMIRNATY® (BNT162b2) vaccine 21-28 days apart, of either 10, 20, 30 µg of vaccine, depending on the observed responses of previous children
Study: NCT06163495

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Screen Free Time with Friends intervention
Description: School-based extracurricular intervention focusing on time spent with friends and screen media use
Study: NCT05422612

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intervention C Placebo
Description: A matching placebo will be administered at 50 mg daily in the same regimen as the intervention.
Study: NCT06686485

Intervention type: DEVICE
Intervention: FARAPULSE™ PFA system and WATCHMAN LAAC Delivery Systems
Description: The FARAPULSE™ PFA System consists of the FARAWAVE™ Pulsed Field Ablation Catheter, the FARASTAR™ Pulsed Field Ablation Generator, and the FARADRIVE™ Steerable Sheath.~The WATCHMAN LAA Closure Technology consists of the WATCHMAN Access System (which consists of the Access Sheath and Dilator and the WATCHMAN Delivery System (which consists of the delivery catheter and the pre-loaded closure device). The WATCHMAN Access System and WATCHMAN Delivery System permit device placement in the LAA via femoral venous access and crossing the inter-atrial septum into the left atrium.
Study: NCT04906213

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 10Mg Placebo Tab
Study: NCT06221540

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Myth busting information leaflet
Description: A written patient information leaflet displaying ten food allergy myths with the myth-busting evidence-based information clearly stated, focusing on themes pertinent to the myth-busting information
Study: NCT06625320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RMC-6236
Description: Oral Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: intravenous (IV) infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nab-paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal irinotecan
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucovorin
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: IV infusion
Study: NCT06625385

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3M™ V.A.C.® Peel and Place Dressing
Description: Application of 3M™ V.A.C.® Peel and Place Dressing used in conjunction with 3M™ V.A.C.® Therapy
Study: NCT06626477

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intra nasal mechanical stimulation treatment (INMEST)
Description: The treatment is performed with the Walther System manufactured by Abilion Medical Systems AB.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Intra nasal mechanical stimulation treatment (INMEST)
Description: The treatment is performed with the Walther System manufactured by Abilion Medical Systems AB.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham (No Treatment)
Description: A modified Walther System not delivering active treatment manufactured by Abilion Medical Systems AB.
Study: NCT05306561

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Systane iLux thermal pulsation treatment
Description: Systane iLux thermal pulsation uses light emitting diode (LED) technology to emit light that is absorbed by pigments (melanin and hemoglobin) in the eyelid. The pigments convert the light energy to heat, which is then transferred to the surrounding tissues, including the meibomian glands. The device heats the eyelid to 40-42°C and maintains it above 40°C during the heating period, which can be 40 seconds or more. This helps melt the meibum. After the heating phase, the meibomian glands are expressed with the built in expression system.
Study: NCT05585684

Intervention type: OTHER
Intervention: Non-invasive Comprehensive Genomic Profiling for Cancer Treatment Selection
Description: Use of liquid biopsy to evaluate the clinical utility of non-invasive comprehensive genomic profiling for cancer treatment selection.
Study: NCT05589363

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABC block with bupivacaine/liposomal bupivacaine
Description: Patients will be randomized to receive an ABC block using bupivacaine/liposomal bupivacaine solution

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: ABC block with saline
Description: Patients will be randomized to receive an ABC block using normal saline
Study: NCT06624956

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glucose, insulin, and potassium (GIK)
Description: GIK formulation: 100 g/L glucose, 33 U/L insulin, and 40 mmol/L KCl~Reference PMID: 32151220. Formulation represents a 50% reduction in compounded solute combination from the reference study, which allows for administration via peripheral IV.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crystalloid Infusion
Description: placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Crystalloid Infusion
Description: placebo
Study: NCT05300139

Intervention type: OTHER
Intervention: Color Doppler Ultrasound
Description: Comparison between D90±5 and baseline CDUS
Study: NCT05971030

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cortical brain stimulation of mPFC and dlPFC
Description: Left medial prefrontal cortex combined with dorsolateral prefrontal cortex electrical stimulation
Study: NCT06171139

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseling Tool
Description: Non-therapeutic educational intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseling Tool
Description: Non-therapeutic educational intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Participants will complete questionnaires online, via mail, by telephone, or in person per participant preference.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Participants will complete questionnaires online, via mail, by telephone, or in person per participant preference.
Study: NCT05980091

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Transvaginal ultrasound
Description: Transvaginal ultrasound throughout the HRT cycle to not only monitor endometrial development but to also exclude the presence of an ovarian dominant follicle
Study: NCT06678022

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: No Drone delivery
Description: Usual ART delivery to landing sites
Study: NCT05980091

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Transvaginal ultrasound
Description: Transvaginal ultrasound throughout the HRT cycle to not only monitor endometrial development but to also exclude the presence of an ovarian dominant follicle

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Serum LH, E2, P4
Description: In conjunction with ultrasound monitoring, participants will undergo serial measurements of serum Luteinizing Hormone (LH), Estradiol (E2) and Progesterone (P4) levels

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Serum LH, E2, P4
Description: In conjunction with ultrasound monitoring, participants will undergo serial measurements of serum Luteinizing Hormone (LH), Estradiol (E2) and Progesterone (P4) levels

Intervention type: DRUG
Group type: OTHER
Intervention: Estradiol Valerate 2 MG
Description: Participants will commence estradiol valerate 4 mg ( 2 x 2 mg) on day 2 / day 3 of menses.~Estradiol will be increased to 6 mg on day 2 of estrogen treatment, and continued at a daily dose of 6 mg (3 tablets daily)

Intervention type: DRUG
Group type: OTHER
Intervention: Estradiol Valerate 2 MG
Description: Participants will commence estradiol valerate 4 mg ( 2 x 2 mg) on day 2 / day 3 of menses.~Estradiol will be increased to 6 mg on day 2 of estrogen treatment, and continued at a daily dose of 6 mg (3 tablets daily)

Intervention type: DRUG
Group type: OTHER
Intervention: Progesterone 100 Mg Vaginal Insert
Description: The initial progesterone dose of 100 mg will be commenced at 13hrs and repeated at 21hrs considered day 1 (vaginal suppository) when an optimal endometrial thickness for each participant has been achieved with a trilaminar appearance. The following day (day 2) progesterone administration will be increased to 100 mg vaginally three times daily

Intervention type: DRUG
Group type: OTHER
Intervention: Progesterone 100 Mg Vaginal Insert
Description: The initial progesterone dose of 100 mg will be commenced at 13hrs and repeated at 21hrs considered day 1 (vaginal suppository) when an optimal endometrial thickness for each participant has been achieved with a trilaminar appearance. The following day (day 2) progesterone administration will be increased to 100 mg vaginally three times daily

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Serum P4 day of ET
Description: On the day of embryo transfer (ET), a blood test is taken to measure serum P4

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Serum P4 day of ET
Description: On the day of embryo transfer (ET), a blood test is taken to measure serum P4

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Embryo transfer
Description: Procedure in which embryo is transferred into the uterus

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Embryo transfer
Description: Procedure in which embryo is transferred into the uterus
Study: NCT06026345

Intervention type: DEVICE
Intervention: Affera Platform
Description: A cardiac ablation will be performed using the Affera Platform
Study: NCT06678022

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fixed Wing drones
Description: Last Mile fixed wing drone delivery
Study: NCT05501210

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WBV
Description: Whole body vibration (WBV) therapy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: WBV
Description: Whole body vibration (WBV) therapy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEMF
Description: Pulsed electromagnetic fields (PEMF)
Study: NCT06682793

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A2B395
Description: Allogeneic logic-gated Tmod CAR T cells

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: xT CDx with HLA-LOH assay
Description: An investigational next generation sequencing (NGS) in vitro diagnostic (IVD) medical device
Study: NCT06684314

Intervention type: DRUG
Intervention: Efanesoctocog alfa
Description: This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practices.
Study: NCT06685718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG-60366
Description: Administered orally
Study: NCT05202574

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous drug
Description: intravenous drug injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous drug
Description: intravenous drug injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous drug
Description: intravenous drug injection
Study: NCT04893629

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mono nuclear cells injection
Description: trans endocardium injection of autologous mono nuclear cells for the intervention group and classic treatment for the control group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Digoxin+furosemide+captopril
Description: classical heart failure medical treatment
Study: NCT05043792

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TT-00920
Description: TT-00920 Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TT-00920
Description: TT-00920 Tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TT-00920 Placebo
Description: TT-00920 Placebo Tablets
Study: NCT06003543

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Virtual Reality
Study: NCT06702722

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Friendship Bench
Description: Friendship Bench problem-solving therapy involving 4 prenatal and 2 postnatal counseling sessions, enhanced for HIV care engagement with 2 social support building sessions and monthly home visits for ART delivery and counseling during the 3rd trimester and the first 3 months postpartum.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced usual care
Description: Usual care for mental health in public facilities in Malawi includes options for basic supportive counseling by a primary provider or nurse, medication management by the primary provider (amitriptyline is the one antidepressant typically available at primary health centers and is rarely prescribed for depression), referral to the clinic psychiatric nurse or mental health clinic, or in more severe cases referral to the psychiatric units at tertiary care hospitals. For the proposed study, usual care will be enhanced to provide a mental health evaluation; brief supportive counseling; information, education, and support on common mental disorders; and (if indicated) facilitation of referral for further follow-up at a mental health clinic or psychiatric unit.
Study: NCT06711198

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality simulation
Description: The student will be put on the Meta Quest 3 virtual reality glasses and the episiotomy application will be started via the computer integrated with the glasses. The episiotomy application will start with the image of a woman who has given birth in the delivery room on the delivery table. The student is expected to select the appropriate materials and complete the episiotomy repair of the woman with the correct steps.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality simulation
Description: The student will be put on the Meta Quest 3 virtual reality glasses and the episiotomy application will be started via the computer integrated with the glasses. The episiotomy application will start with the image of a woman who has given birth in the delivery room on the delivery table. The student is expected to select the appropriate materials and complete the episiotomy repair of the woman with the correct steps.
Study: NCT04654130

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Description: NFB is a type of brain training in which a person is given real-time information (or feedback) from their own brain activities to help them potentially change how their brain is functioning (i.e., to work in a healthier or more effective manner). In the current study, we will implement at-home, supervised (via teleconferencing) neurofeedback sessions using the Muse headband paired with the Myndlift software application to conduct alpha-down neurofeedback once per week, for 19 weeks.
Study: NCT05967156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin10Mg Tab
Description: 10 mg daily
Study: NCT06072170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kratom
Description: Single administration thirty minutes after the start of a high-fat breakfast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kratom
Description: Single administration thirty minutes after the start of a high-fat breakfast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kratom
Description: Single administration thirty minutes after the start of a high-fat breakfast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kratom
Description: Single administration thirty minutes after the start of a high-fat breakfast
Study: NCT05401929

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iTBS
Description: Six trains of active intermittent thetaburst stimulation (iTBS) using neuronavigation-guided cortical targeting to the left dorsolateral prefrontal cortex location using figure-of-8 TMS coils.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: iTBS
Description: Six trains of sham intermittent thetaburst stimulation (iTBS) using neuronavigation-guided cortical targeting to the left dorsolateral prefrontal cortex location using figure-of-8 TMS coils.
Study: NCT06072170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kratom
Description: Single administration thirty minutes after the start of a high-fat breakfast

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single administration thirty minutes after the start of a high-fat breakfast
Study: NCT05798650

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: facial dissatisfaction
Description: Facial dissatisfaction was measured using orofacial aesthetic scale. Participants were asked about how they feel about their smile at that point of time.~The state appearance comparison scale was used to see what the participants thought about their own appearance, their comparison to photographs, and the comparison of their smile, teeth and face to the photographs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: facial dissatisfaction
Description: Facial dissatisfaction was measured using orofacial aesthetic scale. Participants were asked about how they feel about their smile at that point of time.~The state appearance comparison scale was used to see what the participants thought about their own appearance, their comparison to photographs, and the comparison of their smile, teeth and face to the photographs.
Study: NCT04014712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrahydrobiopterin
Description: Oral, Single dose
Study: NCT04454203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepivacaine
Description: An infiltration of mepivacaine superomedially to the femoral artery via perineural catheter.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: An infiltration of saline superomedially to the femoral artery via perineural catheter.
Study: NCT04014712

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Single dose
Study: NCT04693884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Cannabis of (\~10% THC concentration \<1% CBD concentration) will be smoked.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Cannabis of (\~10% THC concentration \<1% CBD concentration) will be vaporized.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Cannabis of (\~10% CBD concentration \<1% THC concentration) will be smoked.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Cannabis of (\~10% CBD concentration \<1% THC concentration) will be vaporized.
Study: NCT04454203

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Perifemoral Injection of Local Anesthetic
Description: Infiltration of mepivacaine superomedially to the formal artery via perineural catheter in an effort to numb the nerves that contribute to tourniquet hypertension intraoperatively.
Study: NCT06685289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donafenib
Description: 200mg, oral, twice daily, continuous medication for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Description: 1250mg/m2, oral, twice daily, treatment for 2 weeks with 1 week off, with 3 weeks as a treatment cycle (a total of 8 treatment cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: 1250mg/m2, oral, twice daily, treatment for 2 weeks with 1 week off, with 3 weeks as a treatment cycle (a total of 8 treatment cycles)